The Federal Trade Commission is currently accepting public comments on an application by Grifols, S.A., a manufacturer of plasma-derived drugs, to amend the terms of a manufacturing agreement that was part of a 2011 FTC-ordered divestiture. The order settled charges that Grifols’ $3.4 billion acquisition of competitor Talecris Biotherapeutics Holdings Corp. was anticompetitive. Under the […]